24
Participants
Start Date
January 31, 2008
Primary Completion Date
December 31, 2009
Study Completion Date
February 28, 2010
Exenatide
The participants with T2DM well-controlled on an intensified insulin regimen for the previous 6 months with the combination of a premeal insulin injection of the drug aspart (Novolog) three times a day and a bedtime insulin injection of the drug detemir (Levemir). The dosage of the insulin is determined by the need by the need of the participant. The Exenatide treatment will consist of an injection of the insulin twice daily and will replace the premeal insulin regiment of aspart.
The University of Texas H.S.C. at San Antonio and the San Antonio Audie L. Murphy VA Hospital, San Antonio
Collaborators (1)
Amylin Pharmaceuticals, LLC.
INDUSTRY
University of Florida
OTHER